News
AMLX
1.890
-2.07%
-0.040
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024
Amylyx Pharma reported earnings per share of -12 cents for the first quarter of 2024. The company reported revenue of $88.64 million. This was below the analyst estimate of $98.35 million. Amylyx Pharmaceutical reported results for the second quarter of 2016.
Investorplace · 9h ago
Amylyx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Amylyx Pharmaceuticals Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 12 cents per share. Revenue rose 24.1% to $88.64 million from a year ago. Amylyx shares have fallen 32.0% this quarter and 86.9% this year.
Reuters · 13h ago
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 14h ago
Amylyx Pharmaceuticals GAAP EPS of -$1.75 misses by $1.76, revenue of $88.64M misses by $9.71M
Seeking Alpha · 15h ago
*Amylyx Pharmaceuticals 1Q Loss $118.8M >AMLX
Dow Jones · 15h ago
*Amylyx Pharmaceuticals 1Q Loss/Shr $1.75 >AMLX
Dow Jones · 15h ago
*Amylyx Pharmaceuticals 1Q Rev $88.6M >AMLX
Dow Jones · 15h ago
BRIEF-Amylyx Pharmaceuticals Q1 EPS USD -1.75
Reuters · 15h ago
AMYLYX PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $373.3 MLN AT MARCH 31, 2024 PROVIDES EXPECTED CASH RUNWAY INTO 2026
Reuters · 15h ago
Notable earnings before Thursday's open
Seeking Alpha · 1d ago
Amylyx Pharmaceuticals Inc <AMLX.OQ> expected to post a loss of 1 cent a share - Earnings Preview
Amylyx Pharmaceuticals Inc expected to post a loss of 1 cent a share. The company is expected to report a 37.7% increase in quarterly revenue to $98.346 million. Amylyx will report results on May 9 for the period ending March 31 2024.
Reuters · 2d ago
Weekly Report: what happened at AMLX last week (0429-0503)?
Weekly Report · 3d ago
Press Release: Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024. The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. The Company will report its first quarter 2024 financial results.
Dow Jones · 05/02 13:07
Weekly Report: what happened at AMLX last week (0422-0426)?
Weekly Report · 04/29 09:26
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Amylyx Pharmaceuticals, Inc. Share price has dived 31% in the last 30 days. The company's price-to-sales ratio of 0.3x is below the average for the Pharmaceuticals industry. Its revenue growth is expected to fall 90% per year over the next three years. Amylyx pharmaceuticals has a low price to sales ratio and a poor outlook for future growth. It's not a good sign for the company's future prospects.
Simply Wall St · 04/25 10:34
Amylyx Pharmaceuticals: Statement of changes in beneficial ownership of securities
Press release · 04/24 10:03
Weekly Report: what happened at AMLX last week (0415-0419)?
Weekly Report · 04/22 09:24
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
TipRanks · 04/16 09:32
Weekly Report: what happened at AMLX last week (0408-0412)?
Weekly Report · 04/15 09:22
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
NASDAQ · 04/12 13:22
More
Webull provides a variety of real-time AMLX stock news. You can receive the latest news about Amylyx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.